A-Alpha Bio Analysis: $45M Raised
What is A-Alpha Bio?
A-Alpha Bio measures and predicts protein-protein interactions using synthetic biology and machine learning. AlphaSeq enables high-throughput measurement of millions of binding affinities. AlphaBind uses a global database to predict binding strength from protein sequence. The company partners with major pharmaceutical firms and academic institutions to advance drug discovery.
Location
Seattle, United States
Employees
51-200
Founded
2017
Funding Status
Series A
Product Features & Capabilities
- AlphaSeq platform measuring millions of protein-protein interactions
- AlphaBind platform predicting binding strength from sequence
- Experimental validation of computational designs
- High-throughput data generation for drug discovery
Use Cases
Predict antibody-antigen binding affinities for therapeutic development; Identify degradable neo-substrates for targeted cancer therapies; Engineer protein interfaces for novel immunocytokines; Validate computational protein designs through experimental measurement; Accelerate discovery of molecular glues for oncology applications
Other Considerations
Measured over a billion protein-protein interactions to date; Partners with Biogen, Gilead, Amgen, and Google; Founded at University of Washington's Institute for Protein Design
See something that needs updating? Suggest edits to this profile.